ASCO and CCF Recognize Cancer Treatment Centers of America® (CTCA) as Vanguard Practices and Largest Donor to CancerLinQ®

November 21, 2016

Cancer Treatment Centers of America® (CTCA) is a national network of five hospitals that provides state-of the-art technologies and innovative cancer therapies to adult patients fighting cancer. CTCA® leadership saw the possibilities and committed to supporting CancerLinQ since its inception in 2014. Its contribution to CancerLinQ, the largest received to date, has greatly helped fund its development and growth over the past two years.

CancerLinQ is a powerful data analytics platform containing a vast amount of clinical cancer information from a fast-growing number of patients. This global initiative will allow cancer researchers and providers to improve the quality and value of care by analyzing millions of patient medical records, uncovering patterns and trends, and measuring their care against that of their peers and recommended guidelines. 

“Consistent with our commitment to the care and treatment of our patients, the development of CancerLinQ will bring the newest evidence-based therapies directly to the patient,” said Raj Garg, MD, JD, President and CEO of CTCA. “We believe that CancerLinQ ranks among the most exciting developments in the evolution of cancer care. We have been delighted to contribute to its development and implementation for the benefit of cancer patients everywhere.” 

CTCA offers an integrative, personalized approach to cancer treatment, serving patients from all 50 states at its hospitals in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. CTCA was also one of the vanguard practices that signed up to participate in CancerLinQ at its earliest stages.

“We are pleased to be part of a network of practices that are able to contribute to the care of patients everywhere,” Maurie Markman, MD, President of Medicine & Science at CTCA. “Having CancerLinQ as a resource will give our providers the insights and information to deliver the care their patients need.”

CTCA is known for its patient-centered integrative care model that focuses on delivering the highest quality of care to patients, their caregivers, Stakeholders and business partners. CTCA clinicians and staff provide patients with comprehensive information about their cancer and treatment options so they can become active participants in their treatment decisions.

Their commitment to individualized patient care mirrors CancerLinQ’s undertaking to learn from real-world cancer data to improve the quality and value of cancer care for each patient.

CancerLinQ is supported in part through the Conquer Cancer Foundation, whose generous donors have helped make the system possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America; Chan Soon-Shiong Family Foundation; Genentech BioOncology™; HELSINN; Janssen Oncology; Lilly; Novartis Oncology; Pfizer Oncology; Raj Mantena, RPh; Susan G. Komen®; and Thomas G. Roberts, Jr., MD, and Susan M. DaSilva.

CancerLinQ is developed by CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology, Inc. (ASCO®). To join in supporting CancerLinQ, please donate to the Conquer Cancer Foundation or email for more information.